July 2025
According to Nova one advisor, the global Erectile Dysfunction (ED) Drugs market size is expected to hit around USD 4.40 billion by 2030 from valued at USD 2.50 billion in 2021 and growing at a CAGR of 8.11% from 2022 to 2030.
The increasing prevalence of erectile dysfunction is expected to contribute to market growth. According to the European Association of Urology, the overall prevalence of ED was found to be around 52% in the European male population aged 40-70 years in 2020. In addition, according to the Boston University School of Medicine, approximately 22.9% of 40 years aged male population and 49.4% by age of 70 years are affected by erectile dysfunction. Thus, the increasing geriatric population is anticipated to increase the prevalence of ED over the forecast period and is expected to create lucrative growth opportunities in the market.
Eli Lilly and Company is supporting ED patients by offering medicine at low cost through Lilly Patient Support Program (LPSP). This program provides financial assistance to eligible ED uninsured patients in Canada who may require registration for this program. Thus, the presence of such supportive programs for a branded version of Cialis may increase the affordability of the lower-income patient population and also aid in generating increased revenue. Moreover, companies have undertaken initiatives such as collaboration and partnership for the manufacturing and commercialization of products in the overseas market. For instance, in January 2022, Petros Pharmaceuticals Inc. partnered with a global Contract Manufacturing Organization (CDMO) for the commercial production of Avanafil tablets. This partnership was formed with an aim to replace the existing agreement with Vivus Inc. and continue product supply.
Furthermore, according to the National Library of Medicine (2021), a phase 3 clinical trial was conducted by Sichuan Haisco Pharmaceutical Co., Ltd. to evaluate the safety and efficacy of Stendra in patients with ED in mainland China. The results of the clinical trial showed improvement in Chinese ED patients after administration of two doses of Stendra 100 mg & 200 mg. Such proven clinical effectiveness may strengthen Strenda’s (Avanafil) position in the market. However, lack of awareness about erectile dysfunction, shame about treatment, false-positive beliefs, social stigma pertaining to the disease, and lack of discretion may restrain the market growth. As per the survey conducted by the European Association of Urology (EAU), only 18% of the Spanish population heard about ED treatment, whereas 68.0% of the population believes the treatment benefits.
Report Scope of the Erectile Dysfunction (ED) Drugs Market
Report Coverage |
Details |
Market Size |
USD 4.40 Billion by 2030 |
Growth Rate |
CAGR of 8.11% from 2022 to 2030 |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
Drug, Distribution Channel And Region |
Companies Mentioned |
· Pfizer Inc. · Eli Lilly and Company · Teva Pharmaceutical Industries Ltd · Sanofi · Sun Pharmaceutical Industries Ltd · Bayer AG · Petros Pharmaceuticals, Inc. · VIVUS, Inc. · Auxilium Pharmaceuticals, Inc. · Adamed |
Increase in Awareness and Patient Education: Key Driver
Narrowing of Insurance Coverage for Erectile Dysfunction Treatment
Regional Insights
North America dominated the erectile dysfunction drugs market and accounted for a revenue share of 52.2% in 2021 due to the high burden of disease, strong healthcare infrastructure, and approval of new products for treatment. In March 2022, Lupin received the U.S. FDA approval for its ANDA for sildenafil (10 mg/mL oral suspension) to market a generic equivalent to Revatio of Viatris Specialty LLC. The accessibility of affordable generic products may increase patient compliance, consequently, increasing the consumer base and revenue for the market
In Asia Pacific, the market for erectile dysfunction drugs is expected to witness fast growth during the forecast period. The growth of the region is attributable to the entry of new products into the region. For instance, in May 2020, iX Biopharma announced the supply of Wafesil and Silcap through telemedicine in Australia for the treatment of an adult patient with erectile dysfunction.
Erectile Dysfunction (ED) Drugs Market: Key Developments
Some of the prominent players in the Erectile Dysfunction (ED) Drugs Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Erectile Dysfunction (ED) Drugs market
By Regional Outlook
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
July 2025
June 2025
June 2025
June 2025